Viatris (VTRS)

[DewDiligence]

MYL’s—(non-exclusive)—Remdesivir-distribution deal for “less-affluent” countries is squarely in its corporate playbook:

https://www.prnewswire.com/news-releases/mylan-to-supply-investigational-antiviral-remdesivir-for-the-potential-treatment-of-covid-19-301058044.html

Under the terms of the license agreement signed with Gilead, Mylan has rights to manufacture and distribute remdesivir in 127 low- and middle-income countries, including India. The agreement is non-exclusive, allowing for multiple licensees to ensure extensive access to this treatment, once approved as safe and effective for COVID-19 patients.

MYL has been doing this with GILD’s HIV drugs for many years.

The profit margins are low, but MYL’s rock-bottom production costs make it doable from a business standpoint.